This plain language summary from Immunotherapy describes the VOLTAIRE-CD study, in which researchers compared BI 695501, a biosimilar to treat Crohn’s disease, with the original drug, adalimumab.

Read the full article here.

The original article on which this plain language summary is based is titled ‘Safety and efficacy of BI 695501 versus adalimumab reference product in patients with advanced Crohn’s disease (VOLTAIRE-CD): a multicentre, randomised, double-blind, phase 3 trial’ and was published in The Lancet Gastroenterology and Hepatology. Read the original article here.